Frank Sciurba
Pulmonary Disease · Pittsburgh, PANPI 1285609545
Payments from drug & device makers
Across 277 payments — averaging $4374.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$438K
- Galvanize Therapeutics, Inc$187K
- Pulmonx Corporation$152K
- Fisher & Paykel Healthcare Limited$121K
- GSK$93K
- Sanofi US Services Inc.$80K
- plus $140K from 10 others
Across 27 payments — averaging $143.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
- Sanofi$1K
- GSK$1K
What the payments were for
- Consulting fees$100,63685%
- Speaking & faculty fees$4,5304%
- Travel & lodging$8,7947%
- Food & beverage$4,9604%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $438,164 |
| Galvanize Therapeutics, Inc | 18 | $187,209 |
| Pulmonx Corporation | 70 | $152,129 |
| Fisher & Paykel Healthcare Limited | 5 | $121,001 |
| GSK | 27 | $93,138 |
| Sanofi US Services Inc. | 12 | $80,111 |
| Verona Pharma, Inc. | 5 | $44,108 |
| Sanofi | 32 | $38,230 |
| Pneumrx, Inc | 7 | $33,148 |
| Genentech USA, Inc. | 15 | $14,339 |
| Regeneron | 11 | $4,694 |
| Astrazeneca AB | 1 | $2,148 |
| Boehringer Ingelheim | 2 | $1,624 |
| Astrazeneca UK Limited | 5 | $1,458 |
| Regeneron Healthcare Solutions, Inc. | 2 | $76 |
| United Therapeutics Corporation | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$10,725
- DUPIXENT$9,372
- ZEPHYR ENDOBRONCHIAL VALVE$8,023
- CHARTIS CATHETER$3,523
- ZEPHYR DELIVERY CATHETER$3,523
- PULMONX CHARTIS TABLET CONSOLE$3,523
- FASENRA$1,746
- AIRSUPRA$1,641
- SPIRIVA$1,500
- ALIYA SYSTEM$249
- TRELEGY ELLIPTA$203
- Esbriet$125
- XOLAIR$125
- Pulmozyme$125
- STIOLTO RESPIMAT$124
- SPIRIVA RESPIMAT$124
How this compares
$1,211,650 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $252,351 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $137,368 |
| NucalaMepolizumab | 15 | $53,783 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 65 | $40,083 |
| Dupixent PenDupilumab | 11 | $39,534 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $24,591 |
| Spiriva RespimatTiotropium Bromide | 26 | $22,529 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,217 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,875 |
| AlvescoCiclesonide | 12 | $3,024 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,954 |
| Theophylline ErTheophylline Anhydrous | 18 | $1,624 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,608 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,305 |
| Azithromycin | 52 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $93,138 | $219,617227 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,624 | $62,61291 claims |
| AstraZenecaSymbicort | $438,164 | $4,21712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Pittsburgh
- Kevin GibsonPittsburgh$1.3M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
- Sally WenzelPittsburgh$676K
- Chadi HagePittsburgh$479K
- Stephen BashedaPittsburgh$456K
- Alison GimbelPittsburgh$304K
- Georgios KitsiosPittsburgh$300K
- Daniel KassPittsburgh$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.